A Unified, Scalable Workflow for Biotherapeutics Developability: ​Automated Assay Analytics from Discovery to CMC​

March 10, 2026

Biotherapeutics comprise a major therapeutic class, but their development brings unique challenges. Developability assessment, including the characterization of key biophysical and biochemical properties such as thermal stability, aggregation risk, and expression efficiency, is essential for selecting viable candidates. While some attributes can be predicted in silico, many require empirical testing in standardized bioassays. To facilitate earlier developability assessment, assay panels are now run at scale on hundreds of antibodies during discovery. This creates significant demands in terms of data processing and ranking many candidates across multiple criteria. Early insights are also increasingly critical for formulation and Chemistry Manufacturing and Controls (CMC) teams, who rely on developability data to anticipate manufacturability and stability risks, enable smoother downstream development, and reduce late-stage failure. This poster shows how Genedata Screener and Chromatics streamline large‑scale developability assessment through automated analysis and integrated data management supporting both discovery and CMC.